Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

World Cancer Day

- PMLiVE

Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat

- PMLiVE

Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment

The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

- PMLiVE

Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer

The combination treatment showed a 35% reduction in the risk of disease progression

- PMLiVE

Lilly announces new study data on Inluriyo in metastatic breast cancer

The five-year survival rate for metastatic breast cancer is 30%

- PMLiVE

Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

The drug treatment is being evaluated in several ongoing phase 3 trials

- PMLiVE

Lilly reports survival benefit with Verzenio in high-risk early breast cancer

The findings are based on Lilly’s phase 3 monarchE trial

- PMLiVE

Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

- PMLiVE

UK government publishes 10 Year Health Plan for England to ‘reinvent’ NHS

The plan’s three overarching themes are hospital to community, analogue to digital and sickness to prevention

- PMLiVE

BioNTech announces £1bn UK investment to boost regional R&D presence

The UK government has also agreed to award the company a grant of up to £129m

- PMLiVE

Researchers uncover promising treatment approach for inherited breast cancer

The study evaluated chemotherapy followed by a targeted cancer drug in patients before surgery

- PMLiVE

Roche’s Perjeta-based breast cancer regimen shows sustained survival benefits

Approximately 56,800 new breast cancer cases are diagnosed in the UK every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links